BEACON Scanner › Sector
Healthcare
150 stocks rated · Under EXPANSION this sector is currently ► Neutral.
Regime Context
Low macro stress, growth accelerating. Cyclicals and growth-oriented sectors are positioned favorably.
The regime overlay applies a sector-level multiplier to every stock's raw BEACON score. Multipliers are confidence-tapered, so borderline regime calls produce smaller adjustments. Read the methodology →
Healthcare Median Fundamentals
| Metric | Median |
|---|---|
| Forward P/E | 11.87 |
| EV / EBITDA | 9.00 |
| P / FCF | 10.33 |
| PEG | 0.09 |
| Gross Margin | +64.2% |
| ROE | -6.6% |
| Debt / Equity | 0.27 |
| FCF Yield | +0.91% |
Based on 150 stocks as of Apr 9, 2026.
Top 10 in Healthcare
Ranked by raw BEACON score| # | Symbol | Company | BEACON | Value | Quality | Momentum | Regime Fit | Adj Score | Sector Rank |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CPRX | Catalyst Pharmaceuticals, Inc. | 78.0 | 77.8 | 85.1 | 68.3 | ► Neutral | 78.0 | 1 / 150 |
| 2 | INCY | Incyte Corporation | 75.5 | 85.9 | 86.3 | 44.0 | ► Neutral | 75.5 | 2 / 150 |
| 3 | EXEL | Exelixis, Inc. | 73.5 | 73.7 | 84.7 | 57.7 | ► Neutral | 73.5 | 3 / 150 |
| 4 | GILD | Gilead Sciences, Inc. | 70.1 | 70.0 | 70.0 | 70.3 | ► Neutral | 70.1 | 4 / 150 |
| 5 | HALO | Halozyme Therapeutics, Inc. | 69.8 | 72.6 | 88.2 | 39.7 | ► Neutral | 69.8 | 5 / 150 |
| 6 | BCRX | BioCryst Pharmaceuticals, Inc. | 69.5 | 57.2 | 75.0 | 81.7 | ► Neutral | 69.5 | 6 / 150 |
| 7 | BMY | Bristol-Myers Squibb Company | 67.1 | 71.6 | 63.3 | 65.0 | ► Neutral | 67.1 | 7 / 150 |
| 8 | JNJ | Johnson & Johnson | 64.2 | 57.1 | 64.4 | 75.3 | ► Neutral | 64.2 | 8 / 150 |
| 9 | BIIB | Biogen Inc. | 63.4 | 68.1 | 66.7 | 51.3 | ► Neutral | 63.4 | 9 / 150 |
| 10 | AMGN | Amgen Inc. | 62.8 | 64.6 | 60.2 | 63.7 | ► Neutral | 62.8 | 10 / 150 |
Interested in gold & mining?
GoldStockData rates 850+ precious metals miners on 11 quantitative signal layers.
Visit GoldStockData →